Of note, impressively decreased mortality has been observed in COVID-19-infected patients treated by various approved medications with implicated NF-κB suppressing activity, such as Aspirin 39, Bruton tyrosine kinase inhibitors (e.g. Ibrutinib, Acalabrutinib) 40,41, Dexamethasone 42, and N-acetyl-cysteine 43. This evidence concerns the gene NFKB1 and COVID-19.